Genetics of Spina Bifida

 

This review is about spina bifida (SB) as a complex congenital disorder of the central nervous system, emphasizing its significant genetic component alongside environmental factors. The authors detail that while the complete cause is not fully understood, research has identified over 250 associated genes in mouse models, pointing to disrupted pathways like the planar cell polarity (PCP) pathway, signaling, and folate metabolism. In humans, SB is considered an omnigenic trait, involving a combination of variants in genes such as VANGL1, VANGL2, CELSR1, and TBXT, as well as genes involved in folate processing like MTHFR. The review also covers the critical role of maternal factors (diabetes, folate deficiency) and the well-established preventive effect of folic acid supplementation. Beyond genetics, the article discusses the pathophysiology of the "two-hit" injury model and the evolution of treatment from postnatal surgical closure to groundbreaking fetal surgery, culminating in the introduction of the first FDA-approved clinical trial using placenta-derived mesenchymal stem cells (PMSCs) to augment in utero repair.

In my opinion, this research paper powerfully illustrates the convergence of genetic discovery and clinical innovation in tackling a devastating birth defect. The genetic narrative is particularly compelling; it moves SB from a condition historically attributed to simple folate deficiency or birth injury to a complex neurogenetic disorder with an "omnigenic" architecture. Understanding that hundreds of genes can disrupt fundamental embryological processes like neural tube closure reframes our approach, shifting focus from a singular cause to a web of vulnerabilities. This genetic complexity explains why folic acid, while hugely preventive, is not a universal cure. The most exciting implication lies in the therapeutic frontier: this genetic understanding lays the groundwork for the pioneering stem cell trial discussed. By identifying the specific cellular and signaling pathways that fail, researchers can now rationally design regenerative strategies, like using PMSCs, to protect or repair the developing spinal cord. This marks a paradigm shift from merely closing a physical defect to attempting a biologically-informed restoration of function, offering real hope for improving outcomes beyond the current limits of fetal surgery alone.

References: 

1. Hassan, A.-E. S., Du, Y. L., Lee, S. Y., Wang, A., & Farmer, D. L. (2022). Spina Bifida: A Review of the Genetics, Pathophysiology and Emerging Cellular Therapies. Journal of Developmental Biology, 10(2), 22. https://doi.org/10.3390/jdb10020022 

2. Spina bifida: MedlinePlus Genetics. (n.d.). Medlineplus.gov. https://medlineplus.gov/genetics/condition/spina-bifida/ 

‌

‌